Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Overview of attention for article published in Clinical Ophthalmology, July 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 3,947 followers.

😷 Aflibercept versus ranibizumab for diabetic macular edema | OPTH - Dove Medical Press 👉 https://t.co/w4EHMm2VI4 💊 #Medical #GroupZirigoza

Reply Repost Favourite

Ophthopedia Update: Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema https://t.co/8rGSM4aitj #Ophthomology #Eye #Ophthotwitter

Reply Repost Favourite